Trial intelligence / Profile preview

Fimasartan on Insulin Secretion and Interaction with DPP4 Inhibitors in Type 2 Diabetes

NCT02312375Completed

Sponsor
Seoul National University Hospital
Start
Mar 2015
Primary completion
Dec 2016
Modality
Small Molecules
Countries
1
01

Overview

Randomised, double-blind trial of fimasartan in type 2 diabetes mellitus (T2DM) and hypertension (HTN), sponsored by Seoul National University Hospital. Primary endpoint: Insulinogenic index at 16 weeks. Started Mar 2015; status: completed.

02

Drugs

fimasartan
03

Conditions

type 2 diabetes mellitus (T2DM)hypertension (HTN)

Beyond the preview

Go deeper on NCT02312375.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NCT02312375.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call